Proceedings of the 50th Hawaii International Conference on System Sciences | 2017

Architecture Enabling Service-oriented Digital Biobanks
Jarkko Hyysalo
University of Oulu
jarkko.hyysalo@oulu.fi

Anja Keskinarkaus
University of Oulu
anjakes@ee.oulu.fi

Abstract
In Finland, the Biobank Act entered into effect in
2013. The primary motivation for the act is to enable
the utilization of collected biological sample material
for medical research. However, in order to effectively
utilize this data, there exists a need to develop new
technological solutions to support the collection and
management of potentially large sets of sensitive data
through multiple stages of processing. The cumulative
data stored within biobanks will enable multidisciplinary research and new innovations. We
propose an architecture that addresses several
challenges involved in defining and deploying a
biobank infrastructure including consent management,
data management and data transfer. Our architecture
expedites the development of this important area within
the research and industrial communities, and enables
the deployment of service-oriented biobanks.

1. Introduction
Biobanks are becoming an increasingly common
method for storing large collections of biological
samples and relevant medical data collected from
donors who have provided consent. There exist many
benefits in creating a locally centralized repository for
including but not limited to allowing researchers access
vast quantities of data that would be otherwise difficult
to obtain from many different sources.
Globally, many hundreds of biobanks exist. In the
European Union, there are currently 315 active
biobanks. Large biobanks currently in operation
include the UK biobank, German National biobank,
The Estonian Genome Center/The Estonian Biobank
cohort and Danish National biobank. Currently, most
scientific publications come from North America,
Great Britain and Central and Southern Europe. Europe
has a common infrastructure BBMRI-ERIC
(Biobanking and BioMolecular resources Research
Infrastructure-The European Research Infrastructure
Consortium) for co-operation. [16, 21]
The guiding principles of the Biobank Act in
Finland (established 1.9.2013) are promotion of trust,
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equal access to data and samples, protection of privacy,
acceleration of innovation activities and exposing
biobank activities to public scrutiny. The primary
motivation for this act coming to pass is to develop a
strong biobank research infrastructure, by overcoming
hurdles like complex collaboration networks, sensitive
data (hard identifiers, sensitive attributes), anonymized
data conflicting with the need to identify subjects and
additionally to identify and satisfy the needs of
multiple stakeholders [19].
In 2015 nine biobanks have been granted the right
to operate by Valvira (National Supervisory Authority
for Welfare and Health) in Finland: Auria biobank,
THL biobank, Finnish Hematological Registry and
Biobank, Helsinki Urological Biobank, Academic
Medical Center Helsinki Biobank, Northern Finland
Biobank Borealis, Finnish Clinical Biobank Tampere,
Central Finland biobank and Biobank of Eastern
Finland. The profiles of the biobanks differ from each
other to avoid redundant effort. There are currently no
commercial biobanks in Finland, and the existing
infrastructures primarily offer sample management and
consultation in marketing and sales [16].
Some research goals would not be feasible without
large biobank collections and the collaboration
between biobanks. Moreover biobanking will require a
consistent, harmonious collection of samples and data.
Without harmonization, the advantage of the
collaboration and data integration to enlarge dataset
from several biobanks is highly non-trivial [10]. This
puts pressure also for updating the representation of
data in already existing collections. This is not a simple
task as biobanks can store data of many distinct types
and employ different data models and formats. Yet, the
various information systems must be integrated with
other information systems to allow both internal and
external interoperability while maintaining and
efficient and secure environment for the data to reside.
The purpose of this paper is to define an
architecture for biobanks that corresponds to the
requirements of a national architecture for biobanks
and address the requirements for harmonization,
national needs and regulations. Hence our research
question: How to define an architecture for a
biobank?. This work is based on extensive
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collaboration between national actors in biobank
domain; Finnish biobanks, software and systems
providers, standardization organizations, hospitals and
several other actors in the health care domain.
The remainder of this paper is organized as follows.
Section 2 discusses the background for this work.
Section 3 presents our research process. Section 4
outlines the proposed biobank architecture and Section
5 discusses the results. Section 6 concludes this work
summarizing the key findings.

2. Background
The biobank shall store collected samples (DNA,
cell tissue etc.) and associated clinical data about the
donors [13] in a locally centralized repository. The
information contained within the biobank is to be made
available for the purposes of medical research.
Management of the data is initiated by the granting of
consent by a donor [4]. Currently the consent or
revocation of consent is provided in written form and
stored [7]. Samples and relevant data are stored within
the biobank in an encoded form. The platform should
handle the management of the data contained within,
so that it can be easily queried and combining results
with auxiliary information is possible. Such data may
include but is not limited to digitized sample material
in the form of whole slide images that may each
occupy multiple gigabytes on disc [8]. When a
researcher or commercial organization expresses
interest in the biobank data (through e.g. a national
catalog), the data is retrieved and passed through a
secondary round of encoding prior to being released.
Auxiliary material is collected from other sources, if
required. The biobank should keep various registers
including coding registry, registry of removed codes,
registers of samples, registers of the utilization of data,
registers for releases and returns of data. The biobank
information management system should also handle
the results of operations upon this data by researchers,
which may of an arbitrary type.

2.1. National consensus
The operating model of the biobanks requires
several stakeholders to give consent, to supervise, to
utilize services, to complement data, to provide finance
and support, to provide services and to provide
common methods. The biobank itself will report these
activities, provide sample and other data, provide
services, and give expertise to BBMRI work to find
and establish common national methods. International
work goes through BBMRI in BBMRI-ERIC. National
Institute for Health and Welfare in Finland (THL) is a

national coordinator of BBMRI work, but also acts in
many other roles. [22]
The Ministry of Health and Social Affairs (STM)
has initiated a national effort on describing the
architecture for biobanks in Finland. The purpose is to
describe the operational environment as well as to
define requirements for efficient operation. The shortterm goal is to enable uniform operating guidelines for
biobanks so that there may exist a national-level
common infrastructure. This is an important window of
opportunity for Finnish research and for international
research networking. [22]
The framework suggests that certain services be
handled in a common way. The management of
consents that are granted or revoked by donors should
reside in a single service. The transfers and material
transfer agreements should also be similarly handled.
Furthermore, it is important that the researcher can see
the available data through an availability catalog
database and in the second level through availability
search service. In this regard, the complexity of the
biobank should be abstracted away behind a single
user-facing interface. Additionally, a coding service
(method to separate actual identity from the stored
data) is planned to be common. Biobanks shall thus
integrate these national services into their own
operational environment. [22]
In the national framework, certain parties have been
suggested to assume control over these services. The
consent register and event register could be part of
Kanta (National Archive of Health Information) and
OmaKanta (portal to personal medical records and
electronic prescriptions). Responsibility of the coding
service is not yet clear. It is important that the coding
service is consistent across several biobanks when data
is combined. The possibility to search all available data
is a necessity to establish a national biobank operation
and could arise from work in BBMRI. Consequently
there should exist a common or at minimum
interoperable information system. This is preceded by
a definition of a reliable method to identify researchers
and to manage access rights to the services. [22, 15]
The biobank is to store data indefinitely or until
consent for the data is revoked. The structure of the
basic data and logic for linking should therefore be
simple. Moreover, the interfaces for data collection and
release should be well defined and easy to use.

2.2. Core components of the biobank IT
infrastructure
Functional
components
of
the
biobank
infrastructure may be divided into four core
components (cf. [1]): 1) Consent tracking; 2) Sample
management; 3) Laboratory processing; 4) Facilitating
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access to data and samples. Forthcoming European
General Data Protection Regulation (GDPR) requires
that informed, explicit consent is necessary [4].
When the samples and related metadata are
processed for inclusion into the biobank, coding,
anonymization and pseudonymization are required.
Sample management includes sample processing,
storage and inventory management. High-speed, large
storage solutions are required (up to 100 TB per year)
[17, 11]. An integral part of the biobank IT
infrastructure is the database for samples and related
metadata. Laboratory processing includes the analysis
and processing of biological samples. Powerful
processing capabilities are required for potential
concurrent analysis of large image files that may be up
to several gigabytes in size. Finally, the distribution of
data and samples to researchers has to be managed.
This requires sufficient information capabilities [15]
including availability services like catalogues to
deliver the data to users. This occurs either through
online viewing or other data distribution methods.
Further components are e.g. firewalls and other
security measures that increase the security, integrity
and redundancy of data. The definition of public and
private APIs is also necessary to enable applications
and services. Standardization and harmonization are
also necessary, as there are differences in operating
procedures between biobanks [2]. This can be due to
local policies or technologies, and transparency is
needed to make the data re-usable [2].

3. Research process
The research consisted of studying several
organizations in related fields with the aim of defining
the architecture. Several workshops with various
organizations were arranged. Approaching our research
question in an iterative manner was viewed as optimal
as there were multiple actors and different domains
involved. The concept was still evolving such that
there were no clear views on how a biobank could be
defined or constructed. Additionally, the requirements
and environment experienced a constant flux as the
laws and regulations were being crafted and refined.
Table 1 presents the organizations and different
sources that participated the definition of the biobank
architecture. The organizations were chosen such that
they all could provide relevant data related to the
research question. Experts and managers from different
organizational levels were involved. Examples of input
defined by the sources are presented in Table 1.

Table 1. Biobank actors.
Source
Valvira

Input
-Biobank permission
-Supervision
Sample donor, person
-Consent
-Samples
KELA (The Social Insurance -Information systems service
Institution of Finland)
THL
-Architecture
-BBMRI-ERIC: Obligations
BBMRI
-Common methods
Registry
-Source data
Service provider
-Service
Health care units
-Sample and data
-Support services
Research
-Sample and data
National ethical board
-Reports
STM
-National biobank overall architecture

Building the outcome iteratively allowed us to see
the results, gather feedback and further improve our
design. This was continued until we were able to draw
the architecture presented in this paper. The intention
was to define an architecture that is not dependent on
specific vendors or components and may be modified
and scaled to meet the future demands. The research
process (Fig. 1) followed the guidelines presented by
Runeson and Höst [18], in an iterative manner.

Figure 1. Research process [18].
In the design phase, the objectives and research
problem in addition to the theoretical background were
determined. Following this, the research methods and
sources were chosen. The preparation phase included
defining the topics to discuss with data sources,
defining the data sources, and agreeing on the
procedures. During the data collection phase, data were
gathered from data sources via numerous workshops
and discussion (first-degree data). This included
collecting archive material such as process descriptions
and workflows provided by the data sources (seconddegree data) and the literature (third-degree data).
Memorandums were made from workshops and
discussions and summarized for all researchers. The
main discussion points, relevant questions and
interesting themes were then extracted from the data
and analyzed further. Data analysis provided further
topics for the following workshops and discussions. An
understanding was gradually built as the process
continued. Then, based on our understanding, the
initial architecture was sketched. This was then
discussed between representatives of participating
organizations. Several discussions and workshops were
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arranged at the companies for the participating
organizations to go through the findings and results.
Feedback from the workshops was incorporated in the
analysis. The results of this process are reported here.

4. Proposed biobank architecture
The complete topology has been separated into
multiple independent domains, grouping related
services. It is possible to assign ownership
responsibilities to each domain and modify the
physical or logical mechanics to meet real-world
requirements while ensuring topological coherence.
This is achieved by strictly defining the input and
output interfaces described for each domain. This
architecture presents the topology of the biobank
infrastructure and does not specify specific
implementation details. The overall architecture is
designed such that each component exists in an
isolated environment communicating with other
components through encrypted sockets. The overall
architecture with an example on service scenario for
both donor and recipient is shown in the Fig. 2.

Figure 2. Overall architecture for the biobank.
Isolation is achieved at the component level
through dedicated virtual machines and at the domain
level by physical hardware. This approach allows for
simplified scalability and allows new services to be
included in the system. Additionally, by isolating
components, the impact of security breaches may be
localized and better contained. Similarly, isolating
components allows for stricter definitions of valid
traffic and thus potentially malicious or erroneous
traffic can be better identified. Furthermore, this
approach enables a heterogeneous collection of
components from multiple vendors to coexist,
communicating using open standard protocols and data
formats. This aids in ensuring the future relevance of
the biobank in constantly evolving medical and
technological environments.
The hospital domain (Fig. 3) represents a
collection of systems and devices upon which the data
from consenting donors is stored. New data sources
may be added within this domain as permission is

granted or access is deemed feasible. Access to each
data source is granted independently and that access is
governed through a formal request procedure.
Additionally, the success of the biobank
infrastructure may encourage the inclusion of data sets
that are of a format that have not yet been considered,
such new data inserted into the biobank from the
research community. As a consequence, the biobank
infrastructure has been designed to be agnostic of data
formats and instead seeks to allow data from multiple
sources to co-exist through a harmonization process.

Figure 3. The hospital domain.
The collection domain (Fig. 4) represents a series
of systems that are utilized in the amalgamation of the
various data sources in the hospital domain in addition
to consent information. The data contained within this
domain is a complete representation of the original
data. An additional benefit of maintaining this
collection of data is that currently the requirements for
encoding and obfuscating the datasets in addition to
what may be included is not currently standardized and
may change over time. By having an exact
representation of the original data it is possible to
ensure the continued compliance to data safety
regulations over the lifetime of the biobank.

Figure 4. The collection domain.
This is designed as such so that in the event of a
catastrophic failure, the biobank may utilize the data
stored within this section to re-build the data set,
bypassing production hospital systems. This is required
as access to the hospital domain systems is limited.
Prior to forwarding a data set to the encoding server for
pseudonymization, a transfer delta is computed of the
data contained within the collection server. This
transfer delta is obtained by combining the unique,
relevant fields from each table in the database that have

3472

been created or modified after the last batch transfer
and for which consent exits.
The collection domain requires the use of a
database running on a dedicated hardware instance that
is directly connected only to the encoding domain and
will expose an encrypted network attached storage
device for each hospital domain system with unique
keys that is then pulled into the collection server. This
database shall mirror the table structure of each
database that exists as a valid source for the biobank.
Data will undergo a harmonization process to ensure
that incoming data is in a format suitable for inclusion
into the biobank while maintaining the original
structure. By mirroring the table structure of the source
data, it is possible to ensure that data is not discarded
unnecessarily and all transformations upon the source
data may be computed non-destructively.
Consent data is transmitted to the consent register,
which is stored within the collection domain. After
consent has been registered, a sample ID created from
the original data is stored within the collection domain
with a Boolean value indicating the status of consent.
The encoding domain (Fig. 5) is responsible for
ensuring that any personally identifying information is
sanitized from the original data set prior to inclusion in
the biobank primary repository.

The staging domain (Fig. 6) facilitates the
physical separation of the systems containing sensitive,
personally identifying information and the sanitized
data within the biobank primary repository. This
domain comprises only a network attached storage
device that may be mounted by only a single device at
any point in time.
Since it is required that the regions containing
sensitive information be entirely separated from the
regions that can be considered general-access, it is
necessary for there to exist an additional separating
region. In this staging region, the encoding service
briefly mounts a remote storage drive and deposits the
encoded data prior to disconnecting. The repository
domain then mounts the drive to fetch the deposited
data. Data deposited in the staging area by the
encoding domain shall be encrypted with the public
key of the repository domain and shall have execution
permissions disabled on the data. Upon successful
mounting, the device shall lock access to the drive until
such time that the connected client disconnects. It is
required that only one device be connected to the
staging domain at a given time to ensure that there
does not exist a possibility for malicious traffic to flow
between the regions.

Figure 6. The staging domain.

Figure 5. The encoding domain.
The encoding domain is additionally responsible
for building up a code registry, which keeps a record of
personally identifying information and primary codes.
For anonymizing data a variety of methods are
available, like encryption, hashing, substitution or
removal of personally identifiable information. We
approach this as follows. Data entering the encoding
server from the collection domain is passed through a
sanitization process generating a unique sample
identifier through a one-way mapping process.
Additionally, fields within the data set may be altered
to prevent exposing identifying information. Upon
completion of the sanitization process, a unique
identifier for each sample processed is transmitted to
the code registry over a secure connection. This
identifier enables authorized personnel to map between
the original samples and the pseudonymized biobank
samples.

The repository domain (Fig. 7) serves as the
primary repository for the data that will be utilized for
research purposes. The primary components of the
biobank are a query server upon which resides a
relational database allowing for queries of arbitrary
complexity. Additionally, there exists a storage
allocation containing non-textual data sets that may
incur a significant storage, bandwidth or computational
cost. Within this domain, there exists a requirement for
the primary database and storage server to have a highavailability and be reasonably fault-tolerant. In Fig. 7
the structure of the repository domain is described,
showing the path of data from the staging domain into
the primary biobank database. The access mechanisms
through which the service domain may communicate
with the biobank primary repository are also detailed.
For data received from the staging domain, it is
necessary to verify the source of the data and
determine that the data is well formed. To do so, an
integration server is utilized to read the retrieved data
and prepare it for inclusion into the primary biobank
database. To effectively serve arbitrary queries into the
database, it is necessary that within the service domain,
a structured request is constructed using prepared
statements and have any potentially malicious
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statements nullified prior to entering the repository
domain. Upon receiving a well-formed request
statement, the query server shall collect the requested
data with textual data represented as a JSON or
similarly trivially readable file for effective parsing by
a web client in the service domain. Additionally, other
non-textual data shall be packaged and transmitted
over a secure connection to complete the request.

Figure 7. The repository domain.
The service domain (Fig. 8) comprises the set of
systems that serve as a boundary layer between the
biobank systems and the formation of requests for
biobank data. In the service domain, an extensible set
of services can be developed facilitating multiple usecases for accessing the biobank allowing for scalable
research efforts. In the basic case, there shall exist an
interface into the biobank served over a secure HTTPS
connection that shall facilitate requesting science data
from within the biobank to the recipient. Prior to
releasing data to external systems, a second round of
data encoding is performed to fully sanitize any data
that is made available from within the biobank.

Figure 8. The service domain.
The use of an interface served over HTTPS,
utilizing modern and open standards allows for there to
not exist a dependency on any one particular type of
environment from which the request is formed. This
platform-agnostic approach ensures that the biobank is
accessible from many types of research environments.
Additionally, there is a possibility for a rapid
deployment of security updates in the event that
vulnerability is discovered. The safety of the data
contained within the primary repository and preceding
domains is paramount and thus there exists a
requirement that modifications can be rapidly deployed
to all data request origin points.

5. Discussion
Identified challenges can be divided into three
categories:
1)
Consent
management
and
anonymization; 2) Sample management and
harmonization; 3) Distribution of data and samples. In
addition, there are technological challenges that exist
in each category. Large-scale infrastructures have an
inherent complexity in their design, construction and
management [21]. Consequently, implementation costs
for large-scale digital pathology environment may be
high [11]. Moreover, technological limitations and
insufficient performance of commercial solutions are
identified [11]. With our architecture we aim to address
all these challenges.
Data transfer requirements are considerable in
digital biobanks. For example a typical tissue sample
of 12x20 mm in size with 20x magnification can result
an image many gigabytes in size. Thus, the transfer of
images will require sufficient bandwidth. It is however
possible to compress the images without introducing
artifacts that measurably impact the quality of the
image. The impact of compression must be validated
prior to conducting an analysis on the data, as different
compression methods may have different effects on
image quality. [5]
Furthermore, the number of large files induces a
storage burden. Rojo [17] estimated that about 100 TB
of storage per year is needed to store the data generated
in a pathology department in a 500 beds hospital.
Hence, the storage investment might be substantial. In
any case, there must be carefully planned storage and
backup systems. Tiered storage systems are suggested
to mitigate the high costs of storage [11].
Interoperability and integration issues are likely to
arise. There are several components and services in a
biobank environment that must be interoperable and
there are various standards and specifications for
enabling an interface [12]. Thus, data harmonization
must be addressed carefully.

5.1. Consent management and anonymization
Given the sensitive nature of the data contained
within a biobank, it is paramount that biobanks protect
the confidentiality of the data according to national and
international laws and regulations. Currently there is
no real consensus regarding managing consents in
biobanks [3]. However, the forthcoming GDPR covers
e.g. consents and data protection.
The permission of the biobank to handle samples
and related information is based upon the existence of
consent. The Biobank Act requires written consent,
with a signature. There is a right for the sample donor
to deny and revoke the consent to the use of samples at
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any time. Despite the national work integrating the
consent management as part of the Kanta system, the
biobank itself has to maintain a register of the
consents. The Biobank Act defines that the donor has a
right to know about the information stored in the
biobank and any usage of said data (log files).
Additionally, donors may elect to get information
about the research done with their data. The initial
requirements
considering
biobank
consent
management with OmaKanta have been defined in
Kääriä et al. [9]. One technical issue is the integration
of the local system to the forthcoming implementation
of the national system as well as the integration to
basic processes of the particular processing
environment.
Protecting the privacy of genetic information
requires that the data or samples are coded or
anonymized. One issue influencing the information
systems is the coding used to pseudonymize the social
security numbers. According to the law, the sample
and related information has to be coded. The
information must be kept separate from the coding key
and the information system must make possible the
secure storage, usage and follow up of the information.
The coding service is defined to include services
related to the separate storage of the identifying
information and samples and the management of the
related coded information. One portion of this is code
registry, which enables associating sample and
information registry data to the information in the
consent registry. The coding service is utilized for
generating secondary codes when releasing data. If
systems do not agree on a compatible coding space,
and hinder or make it more difficult to collect data
from multiple biobanks for research there shall exist a
greater complexity in attaining a coherent and unified
national biobank infrastructure [22].
5.1.1. Our solution to consent management and
anonymization. Input from multiple sources is
amalgamated and sanitized prior to inclusion in the
biobank database. Consent for a data set is verified, the
data is encoded to remove personally identifying
information and any file format specific data is
disassembled into raw meta data and image data prior
to being sent into the biobank database. The collection
domain receives data from sources including, but not
limited to, hospital databases providing data in a
trivially readable format by means of either a direct
connection or by manual file transfer, medical scanners
producing large image files, existing image data
retrieved from PACS servers within the hospital or
data that is manually entered. The sanitization process
for images shall require significant memory if multiple
requests are to be handled simultaneously. However,

since the encoding domain functions as a filter in the
data path, it is not required to store additional copies of
the data passed to it. This data shall exist in its original
form in the collection domain and in its encoded form
in the repository domain.

5.2. Sample management and harmonization
Qpati is one example of a hospital information
management system. It specially designed for the
utilization in pathology departments. The system stores
the sample number, sample types and other relevant
information concerning the samples and has several
device interfaces. For example, it has the capability to
produce barcodes or QR codes for physical samples.
The Qpati system enables analysis, management of
information, storing diagnoses and has in addition
connections to other patient information systems [14].
The Qpati system has been in use in several hospitals
in Finland and updates on the system have gradually
been added, consequently different hospitals may have
a different version in use. Different hospitals may also
use different clinical terms [15].
Harmonization is one of the critical enablers for
achieving a greater effective utilization from biobanks.
Harmonization and sustainability are the two key
strategic priorities to increase interoperability among
international
biobank
infrastructures
[6].
Harmonization at a national level is also necessary and
it is the first step towards global interoperability.
Standard operating procedures and harmonization are
required during sample collection, processing and
storage. Access to comprehensive and well-organized
collections of samples is needed as well as the
associated clinical and research data which in turn
require harmonization of operational procedures and
best practices [6]. Interoperability is essential in
enabling the exchange of data and samples. BBMRI is
also one effort towards harmonization and
development of common research infrastructures.
There exist multiple choices to implement an
infrastructure that facilities these constraints. Currently
there exist commercial products like BC Platforms
(http://bcplatforms.com/), which handle basic biobank
functionality (code, consent, transfer, log registers
sample data management, links to availability
database, data integration), and enable application
development through API interfaces. Similarly, basic
functionality could be achieved with non-commercial
alternatives like Samwise, which is an in house sample
management and information management system used
at FIMM (the Institute for Molecular Medicine
Finland) and THL biobank or Core (Code, Consent and
Transfer Registry application by FIMM). This option is
under consideration by several biobanks. However,
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differences in storing blood sample information and the
needs for pathological sample data vary. Similarly, the
operational environments vary so the system is far
from compliance with existing interfaces and hospital
information systems. However, there is an option to
construct a system from first principles relevant to the
requirements of a particular biobank. The advantage of
this is the possibility to devise innovative solutions and
not rely on a single vendor.
5.2.1. Our solution to information management. We
elected to derive a system based upon the requirements
of a biobank storing pathological samples. In our
solution, the primary database in the biobank will
contain all the relevant data for which a patient has
consented to the inclusion of in addition to all data
generated during use of the biobank. Images and other
non-textual data will be referenced by a URI, which
can be retrieved from the data storage. It is intended
that this database be scalable to accommodate future
growth. Thus, efforts will be made from the
commencement of this research project to facilitate
distributed database schemas.
The hardware for the primary database must have a
high availability and fault tolerance as time in which
the system is not functioning is to be minimized. The
data stored in the primary biobank database shall be
primarily textual data, which will not incur significant
storage cost relative to the image data stored
separately. However, due to the vast number of records
that may be queried, in addition to requests including
image data, there will be a high memory utilization on
this system. It is necessary to include solid-state
storage for optimal disc access times when components
may not be fully retained in memory.
The storage of large images and additional data sets
that may be of an arbitrary type are to be stored in a
scalable array of attached storage devices. This
separation from the primary database is beneficial as it
permits a faster storage mechanism on the primary
database server for many queries that do not contain
image data as it is cost prohibitive to create a large
storage array of solid-state drives. The consequence of
this approach is that there will exist latency for the
real-time visualization of images. However there exist
benefits in the trivial scalability of the storage system
and the ease of creating a distributed file system to aid
in redundancy. To effectively store the large data sets
present within the biobank in addition to facilitating
the scaling of storage capacities to meet future demand,
external storage servers are required. The servers will
be accessible only by the primary database and will
appear as a single unified file system. Effective
redundancy strategies and data protection strategies
must be determined carefully.

Considering harmonization, the information stored
in the Qpati system plays an important role. The aim is
to harmonize usage of terminology by creating a
common term catalog. Accordingly, using Qpati data
provided by different hospitals, all data is converted
into the same code spaces. Automatic conversion using
UMLS can provide conversion of SNOMED (The
Systematized Nomenclature of Medicine) medical
terms into the same code space to some extent.
However, the process needs manual verification for
ensuring the quality of the output. Frequency lists are
created representing the usage of terminology (parsed
from Qpati data) to evaluate how the terms are used
and which variables are more important for automatic
analysis. This harmonization of terminology shall act
as the basis for the build-up of a common availability
service enabling queries over multiple biobanks.
Moreover, tools to provide frequency lists can be
useful also in the actual availability service.

5.3. Facilitating access to data and samples
There is a strong need to ensure confidentiality of
medical data in biobanks. Such requirements are set by
the European Data Protection Directive (Directive
95/46/EC) and in the forthcoming GDPR. Use of
samples and data are subject to strict coding
requirements unless otherwise consented to [19].
BBMRI.fi (Finnish national node of BBMRI) attempts
to address these issues with an infrastructure that
provides various IT tools; such as tools for ensuring
security
like
KITE
availability
service
(https://kite.fimm.fi/), which supports authentication
and REMS (Data request and access approval system).
For facilitating access to data and samples, a
national availability service shall be set up. The
primary goal of a national availability service is to
provide researchers a method to easily locate
appropriate data/samples for research [20].
The definition of biobank research is broader than
the definition of scientific research in other Finnish
laws. Biobank research is defined as research, which
takes advantage of samples and the related information
to improve health, to understand disease mechanisms
and the development of services and practices in health
and patient care. The law additionally includes applied
research targeting products and services [20].
Furthermore, facilitating access to cumulative
digitized data enables e.g. identifying trajectories of
healthy aging and developing new strategies for public
health, including new tools for diagnostics, treatment
and intervention. It will also create possibilities for
new service and business models.
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5.3.1 Our solution to data distribution. Our solution
offers a web server–a boundary layer that facilitates
interaction with the biobank database. In this layer, a
web interface hosted on a physical server will allow
users e.g. to query the biobank database, visualize
image data and obtain statistics on the available data
set. It is recommended that this layer not receive
incoming connections from the internet. This boundary
layer consists of a single physical server that requires
the ability to handle multiple concurrent connections
and service multiple requests. This layer will
experience significant bandwidth consumption during
the visualization of the image data and so there exists a
large memory requirement. All communications
between any two parts of the system in addition to all
storage is to be fully encrypted.
The data catalog is utilized for finding information
about the data that is currently available. This should
be presented to the researchers in commonly agreed
format and with appropriate links to the biobank for
further information if available and methods to search
over included metadata. In order to provide efficient
services, an information pool with appropriate
information collected by biobanks that could be
queried in one location would be optimal. Information
stored in Qpati is just one example of existing
information. In addition hospitals store information in
various other systems. The three-step process of
forming a national availability service is described in
[20]. Work on Qpati data harmonization will open up
the issue by providing scripts and tools for the future.
The catalog and availability service is planned to have
a web-interface, and the already available KITE system
is a good candidate as a platform.
The biobanks have defined basic protocols for
handling research permits in their applications to
Valvira. A scientific board, potentially involving an
ethics committee and external consultants, processes
each research application. Then a written contract is
made with the background organization of the
applicant. The researcher receives the samples and
related information in a coded format. Challenges exist
regarding the confidentiality (what kind of register
information can be obtained about the donor) and on
practices and policies of research results returning to
the biobank as this data should be made available for
future research as well as to the donors.

6. Conclusions
A biobank is a system that amalgamates data from
multiple sources to facilitate multidisciplinary research
by providing a repository for a large number of
samples and any associated data. Data stored within the
biobank is considered to exist in perpetuity and as a

consequence, it is necessary to define an architecture
that utilizes the knowledge of multiple fields spanning
science, technology and medicine to ensure the
relevance of the system in the future. The architecture
presented in this document strives to define a simple
architecture that can be easily scaled to meet the future
demands of the biobank.
The primary considerations in this architecture are
toward the safety and security of the data and services
in addition to ensuring that the internal details of the
system may be abstracted away when the system is
utilized in production. The correctness of the system
and the data stored within it is paramount.
For data to be included into the biobank, consent
must be obtained and stored. Upon such time that
consent is received, the data for which consent is
granted is stored within the biobank and becomes
available to be queried. The data may contain textual
data only, or it may contain image data that may be
multiple gigabytes in size.
Furthermore, there exist many challenges in
implementing a biobank architecture. The system shall
contain highly sensitive data with strict legal guidelines
on how it may be stored and accessed. Implementation
must necessarily enforce the separation of components
both through the use of virtual machines hosting each
component and the use of physical hardware
boundaries to delimit regions of varying data
sensitivity. Additionally, all communication between
any two components and any storage upon which data
resides are to be fully encrypted. While currently many
of these challenges remain as open questions with
regards to specific implementation details, this
architecture attempts to account for a volatile set of
requirements.
The results should interest both academics and
practitioners as they provide an architecture for a
biobank infrastructure. The study also lays the
groundwork for further scholarly inquiry including
validating the findings in practice. For practitioners,
this work provides a better understanding of the key
challenges to be addressed and it defines real needs of
various stakeholders.
There is still a need for further work. For example
the quantity of data potentially handled in biobanks
creates many research problems regarding how to best
index and access the data in a multi-user environment.
Additionally, there exists an opportunity for further
study into the effective integration and interoperability
of biobanks at both a national and international level.
Solutions to these problems will require further studies.
Finally, implementing our architecture and deploying a
functioning biobank environment should follow in
order to better validate our proposed architecture.
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